GI Effects Comprehensive Stool Profile - an assessment for malabsorption, digestive enzyme function, inflammation, overgrowth of pathogenic bacteria, candida and parasites
Many chronic health issues are caused by inflammation in the digestive tract and abnormal levels of yeast/candida, pathogenic bacteria or other parasitic microbes. We offer the GI Effects Comprehensive Stool Profile from Genova Diagnostics to help you find the root cause of your digestive complaints. We offer natural solutions for the following digestive conditions:
- Celiac disease
- Crohn's disease
- Ulcerative colitis
- Gas and bloating
- Malabsorption issues
- Leaky gut syndrome
GI Effects is an innovative stool test measuring biomarkers of gastrointestinal function, digestive performance, gut inflammation and the gut microbiome. It includes the following markers:
Digestion and Absorption:
- Pancreatic Elastase-1, a marker of exocrine pancreatic function
- Products of Protein Breakdown, markers of undigested protein reaching the colon
- Fecal Fat, markers of fat breakdown and absorption
- Calprotectin, a marker of neutrophil-driven inflammation; produced in abundance at sites of inflammation, this biomarker has been proven clinically useful in differentiating between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)*
- Eosinophil Protein X, a marker of eosinophil-driven inflammation and allergic response
- Fecal Secretory IgA, a marker of gut secretory immunity and barrier function
- Additional biomarkers available: Fecal Lactoferrin
- Metabolic indicators demonstrating specific and vital metabolic functions performed by the microbiota
- Commensal bacteria demonstrating the composition, diversity, and relative abundance of gut organisms, all of which are linked to both gastrointestinal and general health.
- More than 95% of commensal gut organisms are anaerobic and are difficult to recover by traditional (aerobic) culture techniques; molecular DNA techniques are now considered the standard for anaerobic bacteria assessment in research, permitting identification and quantification of multiple organisms with a single specimen.
- The Polymerase Chain Reaction (PCR) methodology can identify bacterial populations at any level of taxonomy, as broadly as phylum and as narrowly as species. This ability permits analysis of the gut microbiome at a desired degree of complexity.
- GI Effects assesses a key set of 24 clinically relevant genera/species that map to 7 major phyla.
- Bacterial and fungal culture which demonstrate the presence of specific beneficial and pathological organisms
- Traditional bacterial culture complements DNA-based tests to provide an expanded survey of a patient's gut microbiota, beyond the specific organisms targeted by PCR.
- GI Effects provides microscopic examination of fecal specimens for ova and parasites (O&P), the gold standard of diagnosis for many parasites.
- Enzyme immunoassay (EIA), widely recognized for its diagnostic utility in the detection of pathogenic antigens, is used for the identification of Cryptosporidium, Entamoeba histolytica, and Giardia lamblia.
- Determination of one-day or three-day sample collection is based on clinician's clinical index of suspicion for parasitic infection. If no/low suspicion, a one day sample will likely be adequate. If high suspicion, a three day sample collection is optimal.
- Additional biomarkers available:
- Campylobacter EIA
- Clostridium difficile EIA
- Escherichia coli EIA
- Helicobacter pylori Stool Antigen EIA
- Short-Chain Fatty Acids, a metabolomic indicator of GI microbiome health
- Beta-glucuronidase, an inducible enzyme involved in the metabolism and bioavailability of food and drug compounds; also produced by gut bacteria
Information and lab testing is provided by Genova Diagnostics.